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Abstract
Background—Neisseria gonorrhoeae (gonorrhea) remains an important cause of reproductive 
and obstetric complications. There has been limited population-based research to evaluate the 
association between maternal gonorrhea and adverse birth outcomes.
Methods—A population-based retrospective cohort study was conducted of women with 
singleton pregnancies in Washington State from 2003–2014 using linked birth certificate and birth 
hospitalization discharge data. The exposed cohort consisted of women with gonorrhea diagnosed 
during pregnancy. The unexposed group, defined as pregnant women without gonorrhea, was 
selected by frequency-matching by birth year in a 4:1 ratio. Logistic regression was used to 
determine crude and adjusted odds ratios (OR) for the association of maternal gonorrhea and 
adverse birth outcomes.
Results—Women with gonorrhea during pregnancy (N=819) were more likely to be younger, 
Black, single, less educated, multiparous, and smokers compared to women without gonorrhea 
(N=3276). Maternal gonorrhea was significantly associated with a 40% increased odds (adjusted 
OR 1.4, 95% confidence interval (CI) 1.0–1.8) of low birth weight (LBW) infants compared to 
women without gonorrhea when adjusted for marital and smoking status. Maternal gonorrhea was 
associated with a 60% increased odds (OR 1.6, 95% CI 1.3–2.0) of small for gestational age 
(SGA) infants compared to women without gonorrhea.
Conclusions—This analysis showed that pregnant women with gonorrhea were more likely to 
have LBW infants, consistent with prior literature, and provided new evidence that maternal 
gonorrhea is associated with SGA infants. These findings support increased public health efforts to 
prevent, identify, and treat gonorrhea infection during pregnancy.
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Maternal Neisseria gonorrhoeae infection was associated with low birth weight infants and small 
for gestational age infants in a population-based cohort study in Washington State.
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Introduction
Sexually transmitted diseases (STDs) remain an important cause of reproductive and 
obstetric complications and can have severe adverse effects on pregnant women and infants. 
Neisseria gonorrhoeae (gonorrhea) is the second most prevalent STD in the United States 
and the burden of disease is highest among women 15 to 24 years of age.1 In Washington 
State in 2014, the incidence of gonorrhea infection in women ages 15–24 was 273 cases per 
100,000 women and this has been rising in the past five years.1 Gonorrhea is often 
undiagnosed due to the high prevalence of asymptomatic infections and, therefore, relies on 
screening for detection.2 If left untreated, gonorrhea can be associated with complications in 
women primarily due to the sequela of pelvic inflammatory disease, including ectopic 
pregnancies.3 Multiple studies have shown that maternal gonorrhea is associated with 
preterm birth.4–7 Additional adverse outcomes in pregnancy associated with maternal 
gonorrhea include chorioamnionitis, intrauterine growth restriction (IUGR), and premature 
rupture of membranes (PROM).5 Furthermore, perinatal transmission of gonorrhea to the 
offspring can result in infant blindness, joint infections, and bloodstream infections.3
The Centers for Disease Control and Prevention (CDC) recommends screening for 
gonorrhea at the first prenatal visit in all pregnant women less than 25 years of age and older 
women at increased risk for gonorrhea.3 The CDC only recommends rescreening women for 
gonorrhea in the third trimester if they are considered to be at continued high risk.3 
Screening during pregnancy is important to prevent the adverse effects of gonorrhea, 
however strong evidence for the CDC guidelines for gonorrhea screening in pregnancy is 
lacking.
There has been limited population-based research to evaluate the association between 
maternal gonorrhea infection and adverse birth outcomes. In addition, studies may have been 
hampered by small sample sizes. Older studies may have utilized less sensitive, culture-
based testing to detect gonorrhea. Since 2002, nucleic acid amplification testing (NAAT) for 
gonorrhea has become more widely implemented in screening programs, which may have 
improved the detection of gonorrhea.8 Further population-based cohort studies are needed to 
better characterize the association between maternal gonorrhea and adverse birth outcomes 
to better guide pregnancy screening recommendations and decrease maternal and infant 
morbidity.
This retrospective population-based cohort study used linked Washington State birth 
certificate and birth hospitalization discharge data from 2003 to 2014 to characterize the 
association between gonorrhea infection during pregnancy and adverse birth outcomes 
including low birth weight (LBW), preterm delivery, small for gestational age (SGA), 
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chorioamnionitis, prolonged PROM, and infant neonatal intensive care unit (NICU) 
admission.
Materials and Methods
Study Design & Data Sources
We conducted a population-based retrospective cohort study of women with singleton 
pregnancies in Washington State from 2003–2014. Our primary data source was Washington 
State birth certificate records. Birth certificate data are recorded shortly after delivery and 
submitted electronically to the Washington State Department of Health. Data captured by the 
birth certificate are obtained from the mother, the medical record, and/or health care 
providers. For this analysis, birth certificate data were linked to Comprehensive Hospital 
Abstract Report System (CHARS), which includes maternal discharge and infant birth 
hospitalization data. CHARS records provided information based on International 
Classification of Diseases, Ninth Revision (ICD-9) diagnosis codes. We identified specific 
codes that were used in our analysis through the Center for Medicare and Medicaid Services 
ICD-9 Code Lookup.9 Because all data were de-identified, the Washington State 
Institutional Review Board considered this research to be exempt from review.
Exposure
The exposed cohort was defined as pregnant women with gonorrhea infection. A total of 819 
mothers were included; 800 mothers were identified as having the check box for maternal 
gonorrhea “present and/or treated during pregnancy” selected on their infant’s birth 
certificate and an additional 19 mothers were identified as having ICD-9 codes 098.0–098.8 
in CHARS. All those identified by birth certificate were also identified by ICD-9 code. Only 
the first birth with gonorrhea was included for mothers with more than one pregnancy with 
gonorrhea. The unexposed group, defined as mothers without gonorrhea, was frequency-
matched by birth year in a 4:1 ratio from the remainder of the population of women with 
singleton pregnancies in Washington State from 2003–2014 who had birth hospitalization 
data in CHARS (N=3276).
Outcomes
Primary outcomes evaluated were LBW, preterm delivery, and SGA. Secondary outcomes 
were prolonged PROM, chorioamnionitis, and infant NICU admission. LBW was defined as 
a weight less than 2500 grams, preterm as delivery at less than 37 weeks gestation, and SGA 
as weight below the 10th percentile for gestational age. Gestational age was based on 
standard ultrasound measurements and was documented on the birth certificate. Birth weight 
and gestational age were recorded on the birth certificate and SGA was calculated from the 
birth weight and gestational age variables. High birth weight (greater than 4500 grams), 
post-term (greater than 43 weeks gestation), and large for gestational age infants (weight 
greater than 90th percentile for gestational age, LGA) were excluded from relevant 
analyses.10 We excluded these infants because we were interested in comparing low birth 
weight, gestational age, and size for gestational age to those infants falling within the normal 
range. The variables prolonged PROM, chorioamnionitis, and NICU admission are check 
boxes marked on the birth certificate. Prolonged PROM is defined as premature rupture of 
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membranes for greater than or equal to 12 hours prior to labor. We supplemented diagnoses 
with data from CHARS using the ICD-9 codes 658.1 and 761.1 for prolonged PROM and 
658.4 and 762.7 for chorioamnionitis. The ICD-9 code 761.1 identified PROM affecting the 
fetus or newborn including artificial rupture of membranes (ROM), which is dually coded 
with 658.3. We would not expect artificial ROM to be related to gonorrhea thus those coded 
with both 761.1 and 658.3 were not included as prolonged PROM diagnoses.
Covariates
We investigated the following descriptive maternal covariates from birth certificate data: age 
(≤ 25, 26–34, ≥35 years), race/ethnicity (White, Black, Hispanic, Asian, Native American, 
Hawaiian/Pacific Islander), marital status (married, single), maternal education (≤12 years, 
>12 years), parity (nulliparous, multiparous), maternal cigarettes smoking status (non-
smoker, smoker), maternal diabetes (established or gestational diabetes, no diabetes), use of 
Women, Infants, and Children (WIC) federal assistance program (yes, no), and prior preterm 
births (yes, no). The Adequacy of Prenatal Care Utilization (Kotelchuck) Index, which 
categorizes the adequacy of prenatal care using gestational age and number of prenatal care 
visits (inadequate, intermediate, adequate, intensive), was also calculated from birth 
certificate data. Further description and validation of this index are described elsewhere.11 
Using both birth certificate data and CHARS, we also investigated the following maternal 
covariates: insurance status (insured, government-sponsored, uninsured, other) and presence 
of other maternal infections including chlamydia (ICD-9 099.5), genital herpes (ICD-9 
054.9, 054.1), syphilis (ICD-9 097.9, 090.9), group B streptococcus (ICD-9 041.02, 
V02.51), hepatitis B (ICD-9 070.2, 070.3), and hepatitis C (ICD-9 070.51, 070.54, 070.70). 
The aforementioned maternal infections are also indicated through checkboxes marked on 
the birth certificates. We designated insured as private insurance and Civilian Health and 
Medical Program of the Uniformed Services (CHAMPUS)/Tricare, government-sponsored 
as Medicaid, Indian Health Service, and other government insurance, uninsured as self-pay 
and charity care, and other as other, unknown, or missing.
Statistical analyses
Stata 14.1 software was used for all statistical analyses.12 We first estimated unadjusted odds 
ratios (ORs) for the association between maternal gonorrhea infection and each of our six 
outcomes using univariable logistic regression. Multivariable logistic regression models 
were then created specific for each outcome. Potential effect modifiers were evaluated by 
assessing stratum-specific estimates for meaningful differences using the Breslow-Day test 
for homogeneity.13 If effect modification was present, an interaction term was included in 
the logistic regression model. We evaluated potential confounders using bivariable logistic 
regression. Variables that changed the unadjusted OR by greater than 10% were included in 
the multivariable logistic regression model. Records with missing data on variables for the 
association under investigation were excluded from the relevant analyses. Effect modifiers 
and confounders were selected based on prior studies, biologic plausibility for effect 
modification, and known associations with exposure and outcome for confounders.14–22 We 
evaluated maternal age, diabetes, and prior preterm births for effect modification in our 
analyses of the association between maternal gonorrhea and LBW, preterm delivery, and 
SGA. We investigated diabetes and smoking as effect modifiers for chorioamnionitis and 
Heumann et al. Page 4













evaluated prior preterm birth as an effect modifier for NICU admission. Maternal age, race/
ethnicity, marital status, education, WIC, insurance, Kotelchuck index, smoking status, and 
other infections including chlamydia, genital herpes, syphilis, group B streptococcus, 
hepatitis B, and hepatitis C were assessed as potential confounders for all outcomes. 
Additionally, we conducted restricted analyses comparing the six adverse outcomes among 
the exposed and unexposed within sub-groups of possible confounders including age (≤25 
>25), education (≤12 years, >12 years), and any maternal STD (combined chlamydia, 
herpes, syphilis, hepatitis B, hepatitis C; none). We calculated univariate and adjusted OR in 
each of these sub-groups for the association between maternal gonorrhea and each outcome. 
Any previously identified confounders by the 10% rule for the association between 
gonorrhea and each outcome were adjusted for in multivariable analyses.
We examined patterns of missingness in the data and used Hot Deck single imputation to 
impute values that were similar to the available values in the data matrix to evaluate the 
impact of missingness on our associations. We performed sensitivity analyses with varying 
categorizations of the variables age, insurance, and race. We also performed sensitivity 
analyses for our primary outcomes that included the previously excluded high weight infants 
in the LBW analysis, post-term infants in the preterm analysis, and LGA infants in the SGA 
analysis.
Results
Women with gonorrhea during pregnancy (N=819) were younger and more frequently 
Black, single, less educated, multiparous, and smokers during pregnancy compared to 
women without gonorrhea (N=3276, Table 1). Maternal chlamydia and genital herpes were 
more common in women with gonorrhea infection compared to women without gonorrhea. 
Additionally, women with gonorrhea during pregnancy more frequently received assistance 
from WIC, had inadequate prenatal care by Kotelchuck index, and had government-
sponsored insurance compared to women without gonorrhea infections. Women with 
gonorrhea had a higher prevalence of maternal co-morbidities including diabetes, syphilis, 
hepatitis B, and hepatitis C.
Women with gonorrhea during pregnancy had a 40% increased odds of having an LBW 
infant (adjusted OR [aOR] 1.4, 95% confidence interval (CI) 1.0–1.8) compared to women 
without gonorrhea, when adjusted for marital status and smoking status (Table 2). Similarly, 
maternal gonorrhea infection was associated with a 60% increased odds (OR 1.6, 95% CI 
1.3–2.0) of SGA infants compared to women without gonorrhea infection. There were no 
confounders found for the association between SGA and maternal gonorrhea. Gonorrhea 
infection during pregnancy was not significantly associated with preterm delivery. Maternal 
age, maternal diabetes, and prior preterm births did not modify the association observed 
between maternal gonorrhea and the primary outcomes (LBW, preterm delivery, and SGA).
There were no significant associations between maternal gonorrhea infection and our 
secondary outcomes of chorioamnionitis, prolonged PROM, or infant NICU admission 
(Table 3). The latter association was adjusted for maternal chlamydia infection and smoking 
status. Maternal diabetes and cigarette smoking during pregnancy did not modify the 
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association observed between maternal gonorrhea and chorioamnionitis. Prior preterm birth 
did not modify the association observed between maternal gonorrhea and NICU admission. 
Restricted analyses within each outcome by age, education, and any other maternal STD did 
not substantially change the risk estimates. Maternal gonorrhea infection was associated 
with SGA infants in mothers without any other STD (OR 1.5, 95% CI 1.1–2.1). Our 
missingness and sensitivity analyses did not substantially change the estimates of the 
associations.
Discussion
This analysis showed that after adjusting for confounders, women with gonorrhea were more 
likely to have LBW and SGA infants. Our analysis of preterm delivery and our secondary 
analyses of chorioamnionitis, prolonged PROM, and infant NICU admission showed no 
significant associations with maternal gonorrhea.
Our study joins a prior study, which identified an association between maternal gonorrhea 
infection and LBW.23 This is biologically plausible as gonorrhea can cross the placenta and 
can result in intrauterine growth restriction (IUGR) and subsequently, LBW.24 To our 
knowledge, there have been no prior published studies identifying a link between maternal 
gonorrhea and SGA infants. A retrospective population-based cohort study in Australia 
found maternal gonorrhea infection to be associated with preterm birth, but there was no 
association with SGA.7 Our analysis showed a significant association between maternal 
gonorrhea and SGA, which we suspect may also be explained by maternal gonorrhea 
infection and IUGR, which in turn, could lead to SGA infants.5,25 Our study, as compared to 
this prior study, included more women with gonorrhea infection and this may explain why 
we were able to detect the association between gonorrhea and SGA infants. In subanalyses 
restricted to mothers without any other STD, maternal gonorrhea was still associated with 
SGA infants, further supporting maternal gonorrhea as a risk factor for SGA independent of 
other STDs.
Several prior studies have shown an association between maternal gonorrhea infection and 
preterm delivery, however this association was not shown in our analysis.4–7 The biological 
mechanism of preterm birth associated with maternal gonorrhea infection has been attributed 
to maternal cytokine response and increased fetal corticotropin-releasing hormone in 
response to infection.26 It is possible that the association between gonorrhea infection and 
preterm delivery may be dependent on timing and the trimesters in which the infection was 
acquired, diagnosed and treated, for which we do not have data.
Prior literature has shown an association between gonorrhea infection during pregnancy and 
both chorioamnionitis and prolonged PROM, however this was not demonstrated in our 
analyses.5 We also did not find a strong association between gonorrhea infection during 
pregnancy and infant NICU admissions, despite adequate power. It is possible that the lack 
of association with these secondary outcomes may have been due to residual confounding 
that attenuated our measured association. To our knowledge, there has been no prior research 
investigating the association between maternal gonorrhea infection and infant NICU 
admissions.
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Strengths of our analyses include the large, population-based sample size and biologic 
plausibility of our findings. However, our findings should be considered in light of several 
limitations. First, we do not know which trimester the maternal gonorrhea infection was 
acquired and diagnosed. A prior study found that the association with maternal gonorrhea 
infection and preterm birth was strengthened if gonorrhea infection was diagnosed in the 
first trimester of pregnancy.6 Adverse outcomes associated with infection in the first 
trimester are mechanistically plausible as the first trimester is the key period in which vital 
organs develop. Because we did not know the trimester of infection, we likely included 
infections from all three trimesters, which we would expect to attenuate the associations we 
found. Additionally, we do not have documentation of treatment of gonorrhea or the time to 
treatment. Based on standard medical practice, we would expect all documented gonorrhea 
infections to have been treated soon after identification, particularly in pregnancy, as this is a 
time of frequent medical follow-up if mothers are engaged in prenatal care. Presumptive 
antibiotic treatment of gonorrhea in pregnancy has been previously shown to decrease 
adverse birth outcomes, including low birth weight.27 If all mothers had been promptly 
treated and we still found an association between gonorrhea and both LBW and SGA 
infants, this would support prioritizing gonorrhea prevention efforts. Furthermore, the 
number of gonococcal infections each mother had during each individual pregnancy was not 
known. This information would be important to evaluate for the potential impact of having 
multiple infections in pregnancy compared to a single infection. Our analysis was also 
limited by the fact that births less than 20 weeks gestation are not recorded on birth 
certificates. Many early deliveries are associated with infection, and we were not able to 
evaluate the role of maternal gonorrhea in these cases. The use of birth certificate data and 
CHARS is also limiting given the potential biases that can occur from under-ascertainment 
of exposures and outcomes, misreporting of information on birth certificates, and miscoding 
of ICD-9 diagnoses for the birth hospitalization. We investigated the impact of these 
limitations by performing missingness and sensitivity analyses, which did not change the 
estimates of our associations. Lastly, as with all observational studies, we must consider the 
influence of residual confounding on our findings.
The CDC recommends screening for gonorrhea at the first prenatal visit in all pregnant 
women less than 25 years of age and older women at increased risk for gonorrhea.3 The 
CDC only recommends rescreening women for gonorrhea in the third trimester if they are 
considered to be at continued high risk.3 In support of these guidelines, we found that 
maternal gonorrhea was more common in younger women although maternal age did not 
modify the association observed between maternal gonorrhea and adverse birth outcomes 
including LBW, preterm delivery, and SGA. Furthermore, several additional characteristics 
differed between women with and without gonorrhea infection in pregnancy such as race, 
marital status, proxies of low socioeconomic status, and the presence of other STDs. 
Clinician ascertainment of whether or not women remain at high risk in third trimester is 
subjective and prone to error. With the growing body of evidence that gonorrhea is 
associated with adverse birth outcomes, the potential benefits of screening all women for 
gonorrhea in the first and third trimester should be reconsidered. Further studies that 
delineate the effects of maternal gonorrhea infection by trimester as well as cost 
effectiveness analyses could help to further shape these guidelines.
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In addition to assuring treatment of pregnant women with gonorrhea infection, it is also 
important to treat all of their sex partners in a timely fashion in an effort to prevent 
reinfection. This can be done by a patient referral strategy, in which the infected woman 
recommends her partners be evaluated for medical treatment. Expedited partner therapy 
(EPT) is an alternative strategy, in which patients deliver oral antibiotic treatment for an 
STD to their sex partners, and has been found to be a successful intervention.28 
Unfortunately, gonorrhea resistance has increased in recent years, and oral antibiotic therapy 
is no longer considered first line treatment for gonorrhea.29 Nevertheless, the CDC 
recommends that if a sex partner of a pregnant woman with gonorrhea cannot be linked to 
evaluation and treatment in a timely fashion, expedited partner therapy (EPT) with oral 
antibiotic therapy could be considered, as not treating partners is more harmful than is the 
use of EPT for gonorrhea.28 Yet another strategy for treating partners is concurrent patient-
partner treatment, in which the pregnant women and her partner are treated at the same 
medical visit, as this has been shown to be more effective than a traditional patient referral 
treatment strategy.30 The treatment of sex partners of pregnant women with gonorrhea 
infection remains a challenging public health concern and should be investigated in future 
studies.
In conclusion, our study found that women with gonorrhea were more likely to have LBW 
and SGA infants. Our findings support increased public health efforts to prevent, identify, 
and treat gonorrhea infection during pregnancy in order to decrease adverse birth outcomes.
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n % n %
Maternal age (years)
  ≤25 544 66.4 1237 37.8
  26–34 232 28.3 1545 47.2
  ≥35 43 5.3 492 15.0
Maternal Race/Ethnicity
  White 529 64.9 2291 70.9
  Black 128 15.9 153 4.7
  Hispanic 65 8.1 356 11.0
  Asian 27 3.4 341 10.6
  Native American 44 5.5 79 2.4
  Hawaiian/Pacific Islander 10 1.3 13 0.4
Maternal Education (years)
  ≤ 12 571 70.5 1387 42.8
Multiparous* 439 54.1 1224 37.9
Unmarried 618 76.3 1231 37.7
Prior Preterm Births 40 4.9 63 1.9
Cigarette smoking during pregnancy◊ 272 33.8 314 9.6
Maternal Diabetes 41 5.0 208 9.6
Maternal Chlamydia 391 47.7 43 1.3
Maternal Genital Herpes 124 15.1 116 3.5
Maternal Syphilis 12 1.5 0 0.0
Maternal Group B Streptococcus 231 28.2 671 20.5
Maternal Hepatitis B 9 1.1 12 0.4
Maternal Hepatitis C 15 1.8 5 0.2
Women, Infants and Children (WIC)** 547 71.6 1211 40.8
Kotelchuck 2-Factor Index§
  Inadequate 198 27.2 441 15.5
  Intermediate 141 19.4 585 20.5
  Adequate 252 34.6 1290 45.2
  Intensive 137 18.8 538 18.9
Insurance Type
  Uninsured 10 1.3 37 1.2
  Government-sponsored 602 75.8 1464 45.7
  Insured 181 22.8 1703 53.1



















n % n %
  Other 1 0.1 1 0.0
N=sample size
a








Defined as any cigarette smoking during pregnancy
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